Researchers Uncover Potential Biomarker for Depression in Migraineurs

May 6th 2021, 3:20pm


Using transcranial sonography, researchers uncovered a potential imaging biomarker for depression among migraineurs.

Laryngeal Hypersensitivity Eyed as a Reason Behind Refractory, Unexplained Cough

May 5th 2021, 11:05pm


Laryngeal hypersensitivity may be a key factor in refractory and unexplained cough.

Standardized Total Knee Arthroplasty Pathway Improves Outcomes in Minority Patients

May 5th 2021, 4:00pm


In a minority-predominant patient population, a standardized pathway for total knee arthroplasty was associated with improved outcomes with no change in postoperative complication rates.

Study Assesses Optimal Ages for T1D Screening

May 5th 2021, 12:00pm


Researchers used data fromThe Environmental Determinants of Diabetes in the Young study to assess whether age impacts risk of T1D onset.

B-Cell Depletion May Indicate Reduced COVID-19 Antibody Response Among Patients With MS

May 3rd 2021, 9:47pm


New research demonstrates that patients with multiple sclerosis (MS) who were asymptomatic for COVID-19 had lower antibody levels against SARS-CoV-2, its causative virus, due to having fewer B cells.

Review Probes Migraine’s Hereditary Nature

May 3rd 2021, 5:30pm


In a review, researchers examined potential mechanisms contributing to the hereditary nature of migraine.

How Does Imaging Perform in Diagnosing MPNs?

May 1st 2021, 2:20pm


The current standard calls for bone marrow biopsies, which are invasive and costly.

FDA Approves Oral Dapagliflozin to Slow Kidney Decline

April 30th 2021, 9:26pm


Last year, a data monitoring committee halted the DAPA-CKD trial when it found the evidence of efficacy was overwhelming, after it was shown the trial met all its primary and secondary end points for patients with chronic kidney disease, with and without type 2 diabetes.

Could Cyltezo Be the First Interchangeable Biosimilar in the United States?

April 30th 2021, 8:00pm


Despite the FDA approving 29 biosimilars, none have achieved interchangeability status. Boehringer Ingelheim thinks its adalimumab biosimilar, Cyltezo, may be the first.

New Studies Affirm Safety Profile, Efficacy of Agalsidase Beta in Fabry Disease

April 30th 2021, 12:50pm


About 1 in 3 patients experienced adverse drug reactions in the 2 new safety studies, aligning with earlier reports.